Objectives The present study analysed, for the first time, the effects of the flavonoid quercetin in rats after chronic inhibition of nitric oxide (NO) synthesis with N ø -nitro-Larginine methyl ester (L-NAME).
Objectives The present study analysed, for the first time, the effects of the flavonoid quercetin in rats after chronic inhibition of nitric oxide (NO) synthesis with N ø -nitro-Larginine methyl ester (L-NAME).
Design Rats were divided randomly into five different treatment groups for 6 weeks: (1) vehicle (control, 1 ml of 1% methylcellulose once daily); (2) vehicle plus L-NAME (75 mg/100 ml in drinking water); (3) quercetin (10 mg/kg p.o. once daily); (4) quercetin (5 mg/kg p.o.) plus L-NAME; and (5) quercetin (10 mg/kg p.o.) plus L-NAME.
Methods The evolution of systolic blood pressure, morphological variables, proteinuria, plasma malondialdehyde and nitrite and nitrate concentrations, hepatic glutathione and malondialdehyde content, glutathione enzymes activity and vascular reactivity at the end of the experiment were analysed.
Results Quercetin markedly inhibited the development of L-NAME-induced hypertension. This effect was accompanied by a partial or full prevention of most of the effects induced by L-NAME, such as: (1) increases in the left ventricular and kidney weight indices; (2) proteinuria; (3) renal histological lesions, including hyaline arteriopathy and thickening of the vascular wall with moderate decrease of the lumen; (4) increased endotheliumdependent contraction; (5) increased vascular thromboxane B 2 (TXB 2 ) synthesis; (6) reduced plasma concentrations of nitrites plus nitrates (NOx); (7) increased plasma and hepatic malondialdehyde (MDA) concentrations; and (8) reduced glutathione peroxidase activity. In most cases these effects were dose dependent, but none of them were observed in normotensive animals.
Introduction
Flavonoids comprise a large group of secondary metabolites occurring widely throughout the plant kingdom, including food plants [1] . Quercetin is the most abundant flavonol-type flavonoid in the human diet [2] . Several epidemiological studies have shown an inverse association between dietary flavonoids (mainly quercetin) and mortality from coronary heart disease and incidence of stroke [2] [3] [4] [5] [6] [7] . A very wide range of in vitro biological actions of quercetin support these potential cardiovascular protective effects, including antioxidant [8] , antiaggregant [9] and vasodilator effects [10, 11] and inhibition of vascular smooth muscle cell hypertrophy [12] . Recent studies have pointed out the relationship between reactive oxygen species (ROS) and cardiovascular diseases [13] [14] [15] . We have recently reported that quercetin reduced the elevated blood pressure, the endothelial dysfunction and the cardiac hypertrophy in spontaneously hypertensive rats (SHRs) [16] . These effects were associated with reduced oxidative status, as indicated by the reduced urinary excretion of the prostaglandin 8-iso-PGF 2AE [16] , reduced plasma and hepatic malondialdehyde levels and increased liver glutathione peroxidase activity [17] . However, the effects of flavonoids in other animal models of hypertension have not yet been analysed.
Therefore, in the present study, we have analysed the effects of an oral daily dose of quercetin, the most abundant flavonoid, on the blood pressure, oxidant status and renal, cardiac and vascular alterations induced in rats by chronic inhibition of nitric oxide (NO) synthesis with N ø -nitro-L-arginine methyl ester (L-NAME).
Methods

Experimental protocols
The experimental protocol followed the European Union guidelines for animal care and protection. Male Wistar rats (175-200 g) were used in the study after an adaptation period of 2 weeks for vehicle administration and blood pressure measurements. Rats were assigned randomly to five different treatment groups for 6 weeks: (1) vehicle (control, 1 ml of 1% methylcellulose once daily, n ¼ 9); (2) vehicle plus L-NAME (75 mg/ 100 ml in drinking water, approximately 75 mg/kg per day, n ¼ 9); (3) quercetin (10 mg/kg p.o. by gavage, mixed in 1 ml of 1% methylcellulose once daily, n ¼ 10); (4) quercetin (5 mg/kg p.o., mixed in 1 ml of 1% methylcellulose once daily, n ¼ 10) plus L-NAME; and (5) quercetin (10 mg/kg p.o., mixed in 1 ml of 1% methylcellulose once daily, n ¼ 10) plus L-NAME. The treatment with quercetin was stopped 2 days before the end of the study in order to study the long-term effects of quercetin without the involvement of the effects of acute administration, and on last day the animals were placed in metabolic cages to collect urine for 24 h.
Blood pressure measurements
Systolic blood pressure was measured every week in conscious rats by tail-cuff plethysmography. At least seven determinations were made in every session and the mean of the lowest three values within 5 mmHg was taken as the systolic blood pressure.
Left ventricular and kidney weight indices
At the end of the experimental period, the animals were anaesthetized with diethyl ether, the blood was collected from the abdominal aorta and the hearts were excised; the atria and the right ventricle were then removed and the remaining left ventricles weighed. The left ventricular and kidney weight indices were calculated by dividing the left ventricle and kidney weight by the body weight.
Plasma and urinary determinations
Proteinuria was determined according to Bradford [18] , using bovine serum albumin as standard, and the results were expressed as milligrams of protein excreted per 100 g of rat during 24 h.
Plasma levels of malondialdehyde (MDA) were assessed following the method described by Esterbauer and Cheeseman [19] . An aliquot of 300 ìl of the sample was added to a reaction mixture containing 750 ìl of an acetonitrile solution of 10.3 mmol/l 1-methyl-phenylindole and 225 ìl HCl 35%. Samples were warmed at 458C for 40 min, and centrifuged at 3000 g for 10 min. The absorbance of the supernatants was measured at 586 nm and compared with a standard curve of 1,1,3,3-tetramethoxypropane. Data were expressed as concentration of MDA (ìmol/l). To measure both plasma nitrite and nitrate concentration (NOx), deproteinized plasma samples were incubated with nitrate reductase to reduce nitrates to nitrites. The final concentrations of NOx were determined by adding Griess reagent (1% sulphanilamide and 0.1% naphthylethylenediamine in 5% orthophosphoric acid) to the sample and measuring the absorbance at 560 nm [20] .
Hepatic determinations
Total glutathione content [reduced glutathione (GSH) + glutathione disulphide (GSSG)] was analysed in the supernatant of liver homogenates with 6 volumes of 5% trichloroacetic acid (TCA) centrifuged at 4000 g for 10 min, using the 5,59-dithio-bis(2-nitrobenzoic acid) (DTNB) recycling assay described by Anderson [21] . Data were expressed as nmol glutathione/g weight of liver.
Enzyme activities were determined in the supernatant of liver samples homogenized with 5 volumes of 0.1 mol/l potassium phosphate, 1 mmol/l ethylendiamine tetracetic acid (EDTA) (pH 7.2) and 0.1% digitonin, and centrifuged at 3000 g for 10 min. Protein concentration was determined according to Bradford [18] . Liver glutathione peroxidase (GPx) activity was determined according to the method described by Flohé and Gü nzler [22] , following the oxidation of NADPH at 340 nm. Homogenate samples containing 20 ìg of protein were incubated for 3 min in the presence of 10 mmol/l GSH, 1.5 mmol/l NADPH, 40 mmol/l NaN 3 , glutathione reductase (0.24 U), and 1.5 mmol/l H 2 O 2 in sodium phosphate 0.1 mol/l pH 7.2. One unit of GPx was defined as the amount of enzyme that catalyses the oxidation of one micromole of NADPH per minute.
Glutathione reductase (GRed) activity was assessed according to the method of Carlberg and Mannervik [23] , following the oxidation of NADPH at 340 nm in a reaction at 308C. Homogenate samples were incubated in the presence of 20 mmol/l GSSG and 2 mmol/l NADPH in 0.2 mol/l potassium phosphate buffer (pH 7.2) containing 2 mmol/l EDTA. One unit of GRed was defined as the amount of enzyme that catalyses the oxidation of one micromole of NADPH per minute.
Tissue levels of malondialdehyde were determined as an index of lipid peroxidation, following the method described by Zingarelli et al. [24] . Liver samples were homogenized in 1.15% KCl solution. An aliquot of the homogenate was added to a reaction mixture containing 200 ìl of 8.1% sodium dodecyl-sulphate, 1500 ìl 20% acetic acid (pH 3.5), 1500 ìl 0.8% thiobarbituric acid and 700 ìl distilled water. Samples were then boiled for 1 h at 958C and centrifuged at 3000 g for 10 min. Supernatant absorbance was measured by spectrophotometry at 532 nm and compared with a standard curve prepared from different concentrations of 1,1,3,3-tetramethoxypropane. Data were expressed as ìmol/l per 100 mg weight of liver.
Histological techniques
Buffered 4% formaldehyde-fixed, paraffin-embedded transverse sections of the superior pole of the kidney were stained with haematoxylin and eosin, MassonGoldner trichromic stain, and periodic acid-Schiff stain. The extent of vascular injury (stenosis, hyaline arteriopathy, proliferative arteriopathy, and fibrinoid necrosis) was assessed by examining profiles of arteries and arterioles in a single kidney section. The presence of glomerular lesions (glomerulosclerosis, collapse, necrosis and microaneurysm) was evaluated in at least 100 glomeruli. Tubular atrophy, tubular casts and tubular dilation were also evaluated. The morphological study was done in blinded fashion on 4 ìm sections with light microscopy, using the most appropriate stain for each lesion. The values were expressed as the percentage of rats with lesions in each group, and the severity of lesions was calculated semi-quantitatively using a 0 to 3+ scale [À, absence; +, mild (, 10% of vessel, tubules or glomeruli involved); ++, moderate (10-25%); +++, severe (.25%)] [25] .
Vascular contractility in vitro
Descending thoracic aortic rings (3 mm) dissected from animals were mounted in organ chambers filled with Krebs solution (composition in mmol/l: NaCl, 118; KCl, 4.75; NaHCO 3 , 25; MgSO 4 , 1.2; CaCl 2 , 2; KH 2 PO 4 , 1.2; and glucose, 11) at 378C and gassed with 95% O 2 and 5% CO 2 . Rings were stretched to 2 g of resting tension by means of two L-shaped stainless-steel wires inserted into the lumen and attached to the chamber and to an isometric force-displacement transducer (Letigraph 2000, Cibertec S.A., Madrid, Spain), respectively, as previously described [10, 16] . In endothelium-denuded vessels, concentration-response curves to noradrenaline (10 À9 -10 À5 mol/l) or KCl (8-80 mmol/l) were constructed by cumulative addition of the drugs. In these aortic rings, no relaxant response to 5 3 10 À6 mol/l acetylcholine was observed. The concentrationrelaxation response curves to nitroprusside (10 À10 -10
À5
mol/l) were performed in rings pre-contracted by 10 -6 mol/l noradrenaline. The relaxant responses to acetylcholine (10 À8 -10 À5 mol/l) were also studied in intact vessels pre-contracted by 10 À7 mol/l noradrenaline with or without the cyclooxygenase (COX) inhibitor indomethacin (10 À5 mol/l). Contractions evoked by acetylcholine were tested in rings with endothelium which were initially stimulated with 80 mmol/l KCl. After washing with Krebs solution and incubation for 30 min with or without SQ-29,548 (10 À7 mol/l) and with L-NAME (10 À4 mol/l), acetylcholine was added in a cumulative fashion (10 À8 -10 À4 mol/l). In this experiment, the contractile responses to acetylcholine were expressed as a percentage of the response to KCl.
Thromboxane B 2 production in aortic rings
To determine the production of TXB 2 , endotheliumintact aortic rings from different experimental groups were placed in 2 ml of Krebs solution bubbled with 95% O 2 and 5% CO 2 gas mixture and kept at 378C in the presence of L-NAME (10 À4 mol/l) and stimulated by 10 À4 mol/l acetylcholine for 15 min. At the end of this period, 500 ìl of the medium were collected and TXB 2 was measured by an enzyme immunoassay (Amersham Life Science, Buckinghamshire, UK).
Vascular nitric oxide synthase (NOS) activity
NOS activity in aortic homogenates was determined by monitoring the conversion of L- [26] . Samples were incubated at room temperature for 30 min with 100 ìl of buffer containing 10 mmol/l N-2-hydroxyethylpiperazine-N-2-ethanesulphonic acid (HEPES) (pH 7.4), sucrose (0.32 mol/l), EDTA (100 ìmol/l), dithiothreitol (1 mmol/l), phenylmethylsulphonyl fluoride (1 mg/ml) and leupeptin (10 ìg/ml), in the presence of the NADPH (1 mmol/l) and a mixture of unlabelled and L-[ 3 H]arginine (10 ìmol/l, 1 ìCi/ml). Another series of samples were incubated in presence of 1 mmol/l ethyleneglycoltetraacetic acid (EGTA). Incubations were terminated by the addition of 20 mmol/l HEPES (1 ml, pH 5.5) containing 1 mmol/l EGTA and 1 mmol/l EDTA. L-[ 3 H]citrulline was separated from arginine by adding 1.5 ml of a 1 : 1 suspension of Dowex (50 W) in water. The radioactivity was measured in the supernatants by liquid scintillation counting.
Vascular NOS and COX expression
Endothelial NOS (eNOS), inducible NOS (iNOS), COX-1 and COX-2 protein expression was measured in the supernatant of aortic homogenates. Western blots were performed with 75 ìg of protein per lane. Sodium dodecyl sulphate (SDS)-polyacrylamide (8 or 12% for NOS or COX, respectively) electrophoresis was performed in a mini-gel system (Bio-Rad Laboratories S.A., Madrid, Spain). The proteins were transferred to nitrocellulose membranes overnight and incubated with eNOS or iNOS rabbit polyclonal antibodies (1 : 1000 dilution; Transduction Laboratories, Becton Dickinson Biosciences, Madrid, Spain), rabbit anti-COX-1 polyclonal (1 : 1000 dilution; SantaCruz Biotechnology, Santa Cruz, California, USA) or rabbit anti-COX-2 polyclonal (1 : 1000 dilution, SantaCruz Biotechnology) and then with the secondary goat antirabbit antibody (SantaCruz Biotechnology). The bands were visualized by chemiluminiscence (ECL, Amersham).
Drugs
All drugs and chemicals were obtained from Sigma (Alcobendas, Spain), except SQ-29,548 (ICN Biomedicals, Inc., Barcelona, Spain) and dissolved in distilled deionized water, except for quercetin, which was mixed with 1% methylcellulose and indomethacin which was prepared in 2 mmol/l Na 2 CO 3 immediately before use.
Statistical analysis
Results are expressed as means AE SEM. Statistically significant differences were calculated by an ANOVA analysis followed by Bonferroni's correction. P , 0.05 was considered statistically significant. Concentrationresponse curves were fitted to the logistic equation:
, where E max is the maximal effect, k is a factor which represents the slope of the curve, and pD 2 is the drug concentration exhibiting 50% of the E max expressed as negative log molar.
Results
Blood pressure and left ventricular and kidney weight indices
Rats receiving L-NAME showed a progressive increase in systolic blood pressure as compared to control rats. This increase was already significant after the first week and reached approximately 50 mmHg at the end of the 6 weeks of treatment. Concomitant treatment with quercetin (5 and 10 mg/kg) reduced the increase in systolic blood pressure induced by L-NAME in a dosedependent fashion. At 5 mg/kg the reduction was significant only after 4 weeks, whereas in rats treated with 10 mg/kg only a weak increase in blood pressure was observed (Fig. 1) . No effect of quercetin was observed in control rats.
At the end of the study period, L-NAME significantly increased the heart (21%), left ventricular (29%) and kidney (22%) weight indices as compared with the control group. In the rats receiving L-NAME plus quercetin at both doses, these parameters were significantly reduced as compared with the L-NAME group (Table 1) .
Renal histology and proteinuria
The renal lesions in rats treated with L-NAME were present in vascular, glomerular and tubulointerstitial areas. Table 2 lists the results of the semiquantitative morphological evaluation. Hyaline and proliferative arteriopathy were the main and most intense lesions, and thickening of the vascular wall with moderate decrease of lumen was observed in 100% of the rats in the L-NAME group, almost always in medium-sized vessels. L-NAME rat groups also presented glomerulosclerosis with prominent increase of mesangial matrix in scattered glomeruli, many hyaline casts, tubular necrosis, and mild and scattered tubular atrophy. A notable result was that 5 or 10 mg/kg quercetin prevented, in part, the hyaline arteriopathy and the vascular hypertrophy in L-NAME-quercetin-treated rat groups, and the renal parenchyma showed only mild glomerular and tubulointerstitial injury without tubular necrosis. Quercetin-treated groups exhibited similar Systolic arterial pressure as measured by tail-cuff plethysmography in control (s), quercetin (d), N ø -nitro-L-arginine methyl ester (L-NAME) (h), L-NAME plus 5 mg/kg quercetin (m) and L-NAME plus 10 mg/kg quercetin (j) groups. Values are expressed as means AE SEM. Ã , P , 0.05 L-NAME versus control group; þ , P , 0.05 quercetin-treated versus untreated group. morphological features to the control group, in which no vascular, glomerular or interstitial lesions were found (Fig. 2) .
Proteinuria was markedly increased in the L-NAME group and this effect was markedly reduced only by 10 mg/kg quercetin (Fig. 3) .
Ex vivo vascular reactivity and NO and COX pathway
In aortic rings, no differences were observed among groups in the endothelium-independent vasodilator responses to the NO donor sodium nitroprusside or to the vasoconstrictor responses induced by noradrenaline or KCl (Table 3) . However, aortae from L-NAMEtreated rats showed strongly reduced endotheliumdependent vasodilator responses (Fig. 4) and increased endothelium-dependent vasoconstrictor responses to acetylcholine (Fig. 5) . The aortae from animals treated with L-NAME plus quercetin showed a small increase in vasodilation (Fig. 4a) induced by acetylcholine, as compared to animals from the L-NAME group. When aortic rings were incubated with indomethacin, no differences in relaxant effects of acetylcholine among L-NAME and L-NAME-quercetin groups were found (Fig. 4b) . Moreover, a reduced vasoconstrictor response to acetylcholine was measured in vessels from L-NAME-quercetin-treated rats (Fig. 5a ). Co-incubation of the vessels with SQ-29,548, an antagonist of prostanoid thromboxane-endoperoxide (TP) receptors, almost abolished these contractions (not shown), suggesting Table 2 Morphological features of rat kidney after treatments Values are expressed as percentage of rats with lesions in each group. The intensity of lesions is shown in brackets (+, mild intensity of vascular, glomerular, and tubular lesions; ++, moderate intensity; +++, severe intensity; À, no lesion). L-NAME, N ø -nitro-L-arginine methyl ester. Renal parenchyma in N ø -nitro-L-arginine methyl ester (L-NAME) hypertension model. (a) Intense (+++) hyaline and proliferative arteriopathy with luminal obliteration (arrow) in L-NAME group [periodic acid-Schiff (PAS) 3 400]. (b) Mild/moderate (+/++) hyaline arteriopathy without proliferative change in L-NAME plus 10 mg/kg quercetin (arrowhead). Note normal feature of arteriole (arrow) and luminal diameter in both vessels (PAS 3 400).
that they are mediated by a prostanoid. In fact, TXB 2 production of aortic tissue stimulated by acetylcholine was higher in rings from the L-NAME group as compared to that of the control group (Fig. 5b) . Quercetin treatment, at both doses, was also able to inhibit the increase in TXB 2 production evoked by chronic L-NAME. No changes in COX-1 and COX-2 expression were found in arteries from different experimental groups (Fig. 5c ).
Total NOS activity was significantly reduced in aortic homogenates from rats chronically treated with L-NAME. Chronic quercetin did not modify NOS activity as compared with the control group and did not change the inhibition induced by L-NAME. Similar results were found when the aortic homogenates were incubated in the presence of 1 mmol/l EGTA (Fig. 6) . No changes in eNOS and iNOS expression were found in arteries from different experimental groups (Fig. 6b) .
Plasma and hepatic variables
The plasma from L-NAME-treated animals showed a significant decrease (56%) in NOx levels and an increase (31%) in MDA content as compared to the control group. In L-NAME plus quercetin-treated rats, the levels of NOx were significantly enhanced by 10 mg/kg quercetin and the MDA concentration was reduced by both doses of flavonoid as compared to L-NAME rats (Fig. 7) . Total glutathione liver content was similar among the five experimental groups (Fig. 8a) . However, liver GPx Proteinuria in the experimental groups. Data are means AE SEM. Ã , P , 0.05 versus control group; and þ , P , 0.05 quercetin-treated versus untreated group. Q5 and Q10 indicate 5 and 10 mg/kg quercetin, respectively. L-NAME, N ø -nitro-L-arginine methyl ester Table 3 Parameters of the concentration-response curves to endothelium-independent vasoactive factors (Fig. 8b ) and liver MDA levels (Fig. 8d) were significantly reduced (14%) and increased (41%), respectively, while GRed activity was unchanged by L-NAME treatment. Only the higher dose of quercetin (10 mg/kg) significantly increased GPx activity in L-NAME-treated rats, so that it was restored to the control levels. The GRed activity was significantly increased in all groups of animals treated with quercetin (Fig. 8) , regardless of the L-NAME treatment. As occurred in plasma, both doses of chronic quercetin fully prevented the increase in MDA contents in liver homogenates induced by NOS inhibition.
Discussion
Administration of L-NAME in drinking water induces a progressive increase in arterial blood pressure which is attributed to a reduced synthesis of the vasodilator NO and has been widely used as a model of chronic hypertension (for a review see Zatz and Baylis [27] ). Acetylcholine(Ach)-induced relaxations in the absence (a) and in the presence of 10 À5 mol/l indomethacin (b), in aortae from the control (s), quercetin (d) L-NAME (h), L-NAME plus 5 mg/kg quercetin (m) and L-NAME plus 10 mg/kg quercetin (j) groups. Acetylcholineinduced relaxations were induced in arteries contracted by noradrenaline (10 À7 mol/l). Data are means AE SEM. Ã , P , 0.05 versus control group and þ P, , 0.05 quercetin-treated versus untreated group. (a) Endothelium-dependent contractions induced by acetylcholine (Ach) in aortae from the control (s), quercetin (d) L-NAME (h), L-NAME plus 5 mg/kg quercetin (m) and L-NAME plus 10 mg/kg quercetin (j) groups. Acetylcholine-induced contractions were induced in arteries treated with L-NAME (10 À4 mol/l) and expressed as a percent of the response to 80 mmol/l KCl. (b) TXB 2 production in the incubation media after stimulation with acetylcholine in the presence of L-NAME ( Control NAME NAME Q5 NAME Q10
Q10
The present study shows for the first time that a single oral daily dose of quercetin (5 or 10 mg/kg) markedly inhibited the development of hypertension in rats treated chronically with L-NAME in a dose-dependent manner. This effect was accompanied by a partial or full prevention of most of the effects induced by L-NAME, such as (1) increases in the left ventricular and kidney weight indices, (2) proteinuria, (3) renal histological lesions, (4) increased endothelium-dependent contraction, (5) increased vascular production of TXA 2 , (6) reduced plasma NOx concentrations, (7) plasma and hepatic MDA concentrations and (8) reduced GPx activity. In most cases these effects were dose dependent.
Quercetin exhibits endothelium-independent vasodilator effects in vitro [10, 11, 28] . We have recently observed that quercetin and its main metabolite found in plasma, isorhamnetin [29] , are more potent vasodilators in the isolated mesenteric resistance bed than in conductance arteries [30] . In addition, quercetin (0.1-10 mg/kg) also exerts marked acute vasodilator effects in vivo when administrated intravenously to Wistar rats (authors, unpublished observations). Therefore, a potential mechanism that might contribute to the in vivo antihypertensive effects of quercetin observed in the present study is a direct vasodilator action.
Renal and cardiac injury
Renal injury has been consistently reported after chronic inhibition of NO synthesis [27] . In our study, the L-NAME group presented elevated kidney weight index, glomerulosclerosis with prominent increase of mesangial matrix in scattered glomeruli, many hyaline casts, tubular necrosis, and mild and scattered tubular atrophy. The main and most intense vascular lesion found in L-NAME rats was hyaline arteriopathy and thickening of the vascular wall (proliferative arteriopathy) with a moderate decrease of lumen, which was almost always observed in medium-sized vessels. These Control Q10 NAME NAME Q5 NAME Q10 Control NAME NAME Q5 NAME Q10 Q10 Plasma (A) nitrate plus nitrite (NOx) and (B) malondialdehyde (MDA) content in the experimental groups. Data are means AE SEM. Ã and þ , P , 0.05 versus the control and N ø -nitro-L-arginine methyl ester (L-NAME) groups, respectively. Q5 and Q10 indicate 5 and 10 mg/kg quercetin, respectively.
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histological findings were associated with proteinuria, indicating functional impairment of the glomerular wall barrier. Quercetin prevented the renal hypertrophy and reduced the renal parenchyma and vascular lesions and proteinuria, indicating that quercetin protects, at least partially, from L-NAME-induced renal injury. A modest left ventricular hypertrophy (9-30%) has been found in this model of hypertension [31] . In our study, the heart and left ventricular weight indices were significantly increased in L-NAME-treated rats and these effects were significantly prevented by quercetin, as found previously in SHR rats [16] . This effect may be at least partly due to a reduction in systolic load, which is a potent stimulus for cardiac growth.
Reactive oxygen species ROS have been suggested to contribute to the genesis of atherosclerosis, diabetes, ischaemic heart disease, heart failure and hypertension [13] [14] [15] . The L-NAME model of hypertension has also been associated with increased oxidative stress. One of the major protective systems against oxidant damage is the glutathione redox cycle. GSH has multiple roles as an antioxidant agent. It functions as a scavenger of ROS, including hydroxyl radicals, singlet oxygen, NO, and peroxynitrite. In addition, GSH is a co-substrate for the detoxification of peroxides by GPx. Therefore, GPx is involved in the reduction of peroxides, preventing lipid peroxidation as well as degradation of the membrane phospholipids and the subsequent formation of MDA.
As a result of the action of GPx, GSH is oxidized to GSSG, the accumulation of which in tissues causes a variety of noxious effects. GRed reduces GSSG back to GSH through the reducing power of NADPH [32] . Plasma GPx is assumed to be synthesized by and secreted from the liver. Therefore, hepatic GPx, together with plasma MDA values reflect not only the liver oxidative status but also probably more general indices of the oxidative status and lipid peroxidation [33, 34] . We found decreased hepatic GPx activity and increased plasma and liver contents of MDA in L-NAME-treated animals. All these results indicate that this model of hypertension is associated with altered glutathione redox cycle and are consistent, as previously reported, with an increased oxidative stress [35, 36] . Flavonoids are considered an important component of dietary antioxidants [8] . In vitro, quercetin scavenges superoxide, hydroxyl radical, peroxynitrite and NO and, after oral administration, quercetin metabolites retain the antioxidant properties of the parent compound [8, 37] . In vivo, long-term quercetin treatment of SHR rats reduced the 24-h urinary levels of isoprostane F 2AE [16] , a prostaglandin-like compound produced by the reaction of arachidonic acid and superoxide, which is widely used as a marker of oxidative stress [38] . In addition, quercetin increased GPx activity in L-NAME-treated (present study) and in SHR rats [17] . However, this is not a direct effect of quercetin, because when liver homogenates were incubated with quercetin, no changes in hepatic GPx activity in SHR or WKY rats were observed [17] . As a consequence of the increased GPx activity, and probably also due to its direct antioxidant effects, quercetin restored the plasma and hepatic content of MDA as enhanced by L-NAME.
All these results indicate that quercetin reduced the Total liver (a) glutathione (GSH) content, (b) hepatic glutathione peroxidase (GPx) and (c) glutathione reductase (GRed) activity, and (d) liver malondialdehyde (MDA) content in the experimental groups. Data are means AE SEM. Ã and þ , P , 0.05 versus the control and N ø -nitro-L-arginine methyl ester (L-NAME) groups, respectively. Q5 and Q10 indicate 5 and 10 mg/kg quercetin, respectively. oxidative stress in the hypertensive animals. Furthermore, it had no effect on the markers of oxidative stress (GPx and MDA) in normotensive animals. However, GRed activity, which was similar in control and L-NAME-treated animals, was increased by quercetin, but this effect was unrelated to the hypertensive/ normotensive status.
Endothelial dysfunction, NO and COX-derived vasoconstrictors
Administration of L-NAME is associated with endothelial dysfunction [27, [39] [40] [41] . L-NAME-treated rats showed strongly reduced endothelium-dependent vasodilator responses induced by acetylcholine. However, quercetin only weakly prevented this effect. The COX inhibitor, indomethacin, also produced a similar weak preventive effect and, in its presence, quercetin did not produce any further effect. In addition, increased endothelium-dependent vasoconstriction induced by acetylcholine was also observed in the L-NAMEtreated rats. This effect was abolished by quercetin and by the thromboxane-endoperoxide (TP) receptor antagonist SQ-29,548, indicating that it can be attributed to increased endothelial release of vasoconstrictor prostanoids, as previously described in this model [40] [41] [42] . In fact, TXB 2 production stimulated by acetylcholine was increased in endothelium-intact aortic rings from L-NAME-treated animals and this increase was prevented in those from quercetin-treated rats. However, no changes in neither COX-1 nor COX-2 expression were detected among the different treatment groups. Taken together, these results indicate that: (1) the L-NAMEinduced reduction of the endothelium-dependent vasodilator effect of acetylcholine is not only due to reduced NO synthesis through NOS activity inhibition but also to vasoconstriction secondary to increased TXA 2 release; (2) quercetin only prevented the latter effect. Thus, a reduction in the release of endotheliumdependent constrictor factors (such as TXA 2 ) might also contribute to the blood pressure lowering effect of quercetin in this model. L-NAME inhibits the constitutive Ca 2þ -dependent NOS isoforms (eNOS and nNOS) and the Ca 2þ -independent inducible NOS isoform (iNOS) [43] . Consistently, in the present study both total and Ca 2þ -independent (iNOS) NOS activities were reduced in aortic homogenates from L-NAME-treated rats. In addition, the data of endothelial dysfunction ex vivo also confirms that eNOS-dependent relaxation is strongly reduced. Moreover, L-NAME-treated animals showed reduced plasma NOx concentrations (NO 2 À plus NO 3 À , which are the main plasma metabolites of NO) (present results, [35, 36] ). However, these inhibitory effects on NOS activity were not associated with changes in NOS expression in aortic tissues. Quercetin did not modify the endothelium-dependent relaxation in the presence of indomethacin, suggesting that it does not alter the NO-dependent component of this relaxation. In addition, quercetin did not restore the impaired Ca 2þ -dependent and -independent NOS activities and did not modify the expression of NOS proteins. Thus, although chronic quercetin prevented the secondary changes in endothelial function (due to increased release of endothelial vasoconstrictors) it was unable to restore the primary defect of endothelial dysfunction (i.e. due to deficient NO production). In contrast, quercetin increased plasma NOx in L-NAME-treated but not in control rats. These results suggest that, despite the fact that quercetin did not modify aortic NOS activities, it might increase them in other tissues. It has been reported recently that quercetin increased aortic NOS activity in Sprague-Dawley rats [44] . However, the oral dose of quercetin used in that study was approx. 25-50 times higher than the one used in the present study. Thus, it is possible that the aorta is less sensitive to the effect of quercetin than other tissues.
ROS, hypertension and end-organ damage: pleiotropic effects of flavonoids ROS, NO and blood pressure are intimately related. Superoxide reacts rapidly with NO, limiting its biological activity. In addition, superoxide also stimulates the production of vasoconstrictors [38] . Thus, increased superoxide production has been proposed to be an important factor contributing to endothelial dysfunction and hypertension [45] . Conversely, increased blood pressure can lead to enhanced ROS production. Superoxide and superoxide-producing enzymes are enhanced in different models of systemic hypertension, regardless of the hypertensive stimulus, and they can be restored by blood pressure-lowering drugs [46, 47] . High blood pressure is an important determinant of hypertrophy and injury to the heart and kidney, but the associated reduced NO and excess ROS are also powerful stimuli for tissue damage.
As discussed above, quercetin has been reported to exert many different effects in vitro that may participate in its antihypertensive effects in vivo. First, it produces direct vasodilator effects. Second, it reduces oxidative stress by: (1) a direct ROS scavenging effect; (2) its metal chelation properties; and (3) inhibition of ROS-producing enzymes such as xanthine oxidase, NAD(P)H oxidase and the mitochondrial complex I. In addition, in vivo, it is able to restore the activity of antioxidant enzymes such as the GPx, and reduces the release of COX-derived vasoconstrictors. All these results suggest that the antihypertensive effects and end-organ protection of quercetin are due to multiple mechanisms of action, operating simultaneously.
In conclusion, the present study demonstrates that quercetin, at doses that can be achieved in the human diet, prevented the elevated blood pressure, the cardiac and renal hypertrophy, the renal parenchyma and vascular lesions, blunted the enhanced endotheliumdependent vasoconstrictor responses and reduced the proteinuria in this model of chronic inhibition of NO synthesis with L-NAME. Even when the antihypertensive effects of quercetin are not firmly established in humans, the blood pressure-reducing effects and endorgan protection may help to explain the preventive effects of dietary flavonoids in cardiovascular diseases reported in epidemiological studies.
